Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Climb Bio, Inc.CLYM · Entity 5064 | Director · President and CEO | June 27, 2026 | June 30, 2026 |
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director | June 05, 2024 | June 07, 2024 |
| SYNLOGIC, INC.SYBX · Entity 7801 | Director · President and CEO | November 10, 2023 | November 15, 2023 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Climb Bio, Inc.
Report date June 27, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 118,633 |
Reported balance
After 2026-06-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-27 · Exercise / conversion · Acquired 68,750 · Balance 118,633 F1: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock F2: Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 87,731 |
Reported balance
After 2026-06-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-29 · Sale · Disposed 30,902 · Balance 87,731 F3: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs. F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 137,500 |
Reported balance
After 2026-06-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-27 · Exercise / conversion · Disposed 68,750 · Balance 137,500 F5: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F6: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock
F2: Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan.
F3: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.
F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F5: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F6: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.
KYNTRA BIO, INC.
Report date June 05, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2034-06-04 | Direct | 70,000 |
Reported balance
After 2024-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-05 · Grant · Acquired 70,000 · Balance 70,000 F1: Options vest on the earlier of June 16, 2025 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest on the earlier of June 16, 2025 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
SYNLOGIC, INC.
Report date November 10, 2023 · Filed November 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $202.95 · Expires 2027-05-15 | Direct | 0 |
Reported balance
After 2023-11-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-10 · Disposition to issuer · Disposed 5,591 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.25 · Expires 2028-03-14 | Direct | 0 |
Reported balance
After 2023-11-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-10 · Disposition to issuer · Disposed 3,733 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $143.25 · Expires 2028-06-05 | Direct | 0 |
Reported balance
After 2023-11-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-10 · Disposition to issuer · Disposed 3,600 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $118.65 · Expires 2028-10-31 | Direct | 0 |
Reported balance
After 2023-11-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-10 · Disposition to issuer · Disposed 9,999 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.85 · Expires 2029-03-05 | Direct | 0 |
Reported balance
After 2023-11-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-10 · Disposition to issuer · Disposed 12,332 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.50 · Expires 2030-03-10 | Direct | 0 |
Reported balance
After 2023-11-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-11-10 · Disposition to issuer · Disposed 12,352 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F3: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.50 · Expires 2031-03-10 | Direct | 0 |
Reported balance
After 2023-11-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-11-10 · Disposition to issuer · Disposed 18,999 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F4: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.25 · Expires 2032-02-04 | Direct | 0 |
Reported balance
After 2023-11-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-11-10 · Disposition to issuer · Disposed 28,943 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F5: The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.30 · Expires 2033-03-16 | Direct | 0 |
Reported balance
After 2023-11-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-11-10 · Disposition to issuer · Disposed 42,999 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F6: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.30 · Expires 2033-03-16 | Direct | 0 |
Reported balance
After 2023-11-10 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-11-10 · Disposition to issuer · Disposed 8,666 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F7: These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2027-05-15 | Direct | 5,591 |
Reported balance
After 2023-11-10 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-11-10 · Grant · Acquired 5,591 · Balance 5,591 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2028-03-14 | Direct | 3,733 |
Reported balance
After 2023-11-10 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-11-10 · Grant · Acquired 3,733 · Balance 3,733 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2028-06-05 | Direct | 3,600 |
Reported balance
After 2023-11-10 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-11-10 · Grant · Acquired 3,600 · Balance 3,600 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2028-10-31 | Direct | 9,999 |
Reported balance
After 2023-11-10 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2023-11-10 · Grant · Acquired 9,999 · Balance 9,999 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2029-03-05 | Direct | 12,332 |
Reported balance
After 2023-11-10 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2023-11-10 · Grant · Acquired 12,332 · Balance 12,332 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2030-03-10 | Direct | 12,352 |
Reported balance
After 2023-11-10 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2023-11-10 · Grant · Acquired 12,352 · Balance 12,352 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F3: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2031-03-10 | Direct | 18,999 |
Reported balance
After 2023-11-10 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2023-11-10 · Grant · Acquired 18,999 · Balance 18,999 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F4: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2032-02-04 | Direct | 28,943 |
Reported balance
After 2023-11-10 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2023-11-10 · Grant · Acquired 28,943 · Balance 28,943 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F5: The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2033-03-16 | Direct | 42,999 |
Reported balance
After 2023-11-10 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2023-11-10 · Grant · Acquired 42,999 · Balance 42,999 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F6: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2033-03-16 | Direct | 8,666 |
Reported balance
After 2023-11-10 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2023-11-10 · Grant · Acquired 8,666 · Balance 8,666 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F7: These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met. |
Filing footnotes · ownership attribution and instrument terms
F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
F2: The shares subject to this option are fully vested as of the date hereof.
F3: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024.
F4: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025.
F5: The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026.
F6: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.
F7: These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.
Xilio Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2036-06-10 | Direct | 5,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,000 · Balance 5,000 F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ra Pharmaceuticals, Inc.
Report date April 02, 2020 · Filed April 03, 2020
Section 16 reporting ended · disclosed 2020-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.88 · Expires 2029-06-11 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-04-02 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.36 · Expires 2028-09-21 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-02 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share.
F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2020 Filed Aug 7, 2020 23:45 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 3,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-045766 · doc4.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,914 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 09:00 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $16.36 | $0.00 |
DisclosureSEC source: 0001104659-20-042761 · a4.xml · derivative · entry 2 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2028-09-21 F1 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 09:00 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $19.88 | $0.00 |
DisclosureSEC source: 0001104659-20-042761 · a4.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-06-11 F1 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 22:00 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 185,300 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000899243-20-008099 · doc4.xml · derivative · entry 2 Brennan Aoife · CIK 0001714563 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,300 Underlying: Common Stock · 185,300 shares Expires 2030-03-10 F2 · derivative.exercise_date: The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on April 10, 2020, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 22:00 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantCommon Stock | 46,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008099 · doc4.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,067 F1 · shares: The shares of restricted stock were granted on March 10, 2020 (the "Grant Date") and will vest in four equal annual installments on each anniversary of the Grant Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 20:30 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-024248 · doc4.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,767 F1 · shares: On September 23, 2019 (the "Grant Date"), the reporting person was granted 8,000 shares of restricted stock of the company under the company's 2015 Equity Incentive Award Plan as part of a company-wide equity grant that was made to all employees. 100% of the shares of restricted stock will vest 18 months from the Grant Date. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 16:34 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | GrantOption to Purchase Common Stock · Derivative | 15,000 | $0.00 Strike: $19.88 | $0.00 |
DisclosureSEC source: 0001104659-19-035363 · a4.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: On June 11, 2019, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the first anniversary of the grant date of June 11, 2019 or (ii) the Issuer's annual meeting of shareholders in 2020. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 21:06 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 185,000 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0000899243-19-006432 · doc4.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2029-03-05 F1 · derivative.exercise_date: The options vest and become exercisable in substantially equal monthly installments beginning on April 5, 2019 and continuing until March 5, 2023, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:05 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $7.91 | $0.00 |
DisclosureSEC source: 0000899243-18-027889 · doc4.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-10-31 F1 · derivative.exercise_date: The option vests and becomes exercisable as to one-fourth (1/4) of the shares on October 2, 2019, and the remainder will vest at one-forty-eighth (1/48th) of the shares per month thereafter, subject to the Reporting Person continuing to provide services to the Issuer as President and Chief Executive Officer through each such vesting date. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 09:20 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | GrantOptions to Purchase Common Stock · Derivative | 25,000 | $0.00 Strike: $16.36 | $0.00 |
DisclosureSEC source: 0001104659-18-058320 · a4.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-09-21 F1 · derivative.exercise_date: On September 21, 2018, the Reporting Person was granted an option to purchase 25,000 shares of Common Stock. The option will vest and become exercisable in three equal installments on each of September 21, 2019, September 21, 2020 and September 21, 2021. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 21:20 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 54,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0000899243-18-015255 · doc4.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Interim President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: The options vest and become exercisable in substantially equal monthly installments beginning on July 5, 2018 and continuing until June 5, 2022, subject to the Reporting Person continuing to provide services to the Issuer as Interim President and Chief Executive Officer through each such vesting date. Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 20:05 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 56,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0000899243-18-007530 · doc4.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2028-03-14 F1 · derivative.exercise_date: The options vest and become exercisable in substantially equal monthly installments beginning on April 14, 2018 and continuing until March 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.